Abstract 473P
Background
Myelosuppression (CIM) is a common toxicity of cancer chemotherapy. Trilaciclib is a highly potent, selective, and reversible CDK4/6 inhibitor designed to protect HSPC,highly dependent on this pathway during chemotherapy by intravenous (IV) administration, thereby reducing HSPC killing by ascending chemotherapy, and transient T-cell suppression favorably alters the tumor immune micro-environment. Through the literature search, it is found that Trilaciclibe can theoretically be used for bone marrow protection and affect the efficacy of anti-tumor chemotherapy.
Methods
Study enrolled advanced first-line chemotherapy-based solid tumors patients, witch were administered Trilaciclibe (240 mg/m2) intravenously over 30 minutes via CDE within 4 hours prior to daily chemotherapy. To observe the incidence of CIM and the efficacy of anti-tumor therapy.
Results
From October 2023, 20 patients have been enrolled, and 15 patient data has been analyzed. There were 14 males and 1 female; the median age was 69.5 (56-84) years; 4 lung squamous cell carcinoma patients (26.7%), 2 lung adenocarcinoma patients (13.7%), 9 small cell lung cancer patients (60.0%), and 1 endometrial cancer patient (6.7%). Ten patients (66.7%) received primary prevention and 6 (33.3%) received secondary. As of the data statistics, 8 patients (53.3%) received the study drug in Cycle 1, 3 (20.0%) in Cycle 2, 4 (26.7%) in Cycle 3 and 1(6.7%) in Cycle 4. Chemotherapy regimens were according to clinical guidelines. CIM occurred as shown in the table Table: 473P
| CIM | % | CIN | % | CIT | % | CRA | % |
| I | 6.3% | I | 11.3% | I | 7.5% | I | 0.0% |
| II | 5.0% | II | 7.5% | II | 1.9% | II | 5.3% |
| III | 0.6% | III | 1.9% | III | 0.0% | III | 0.0% |
| IV | 0.0% | IV | 0.0% | IV | 0.0% | IV | 0.0% |
| ALL | 11.9% | ALL | 20.8% | ALL | 9.4% | ALL | 5.3% |
Conclusions
As of the reporting date, all patients had not experienced Grade III or higher CIM. More attention is paid in CIT, which shows that Trilaciclibe controls platelets well, providing a better management of CIT. Trilaciclibe showed clear myeloprotective effects in lung and endometrial cancer, effectively improving the safety of chemotherapy in first-line patients.
Clinical trial identification
ChiCTR2400082382.
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Bethune Pioneer Medullary Protection - Bone Marrow Protection Special Scientific Research Fund Project.
Disclosure
The author has declared no conflicts of interest.